BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 6177765)

  • 21. 125I-C1q binding activity of soluble antigen-antibody complexes formed in vitro.
    Soltis RD; Hasz DE
    J Clin Lab Immunol; 1982 Nov; 9(2):121-31. PubMed ID: 6984078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of C1 by soluble IgG aggregates as detected by a novel one-step hemolytic assay that specifically measures the proenzyme form of C1s.
    Doekes G; van Es LA; Daha MR
    J Immunol; 1983 Oct; 131(4):1924-9. PubMed ID: 6604753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The classical complement pathway: mechanism of activation of the first component by antigen-antibody complexes.
    Loos M
    Prog Allergy; 1982; 30():135-92. PubMed ID: 7041131
    [No Abstract]   [Full Text] [Related]  

  • 24. Inhibition of the hemolytic activity of the first component of complement C1 by an Escherichia coli C1q binding protein.
    van den Berg RH; Faber-Krol MC; van de Klundert JA; van Es LA; Daha MR
    J Immunol; 1996 Jun; 156(11):4466-73. PubMed ID: 8666822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetics of C1 activation by a monoclonal anti-C1q antibody and its (Fab)2 fragments.
    Kilchherr E; Schumaker VN; Bianchino AC; Curtiss LK
    J Immunol; 1987 Feb; 138(3):849-55. PubMed ID: 3492535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody density on rat red cells determines the rate of activation of the complement component C1.
    Hughes-Jones NC; Gorick BD; Howard JC; Feinstein A
    Eur J Immunol; 1985 Oct; 15(10):976-80. PubMed ID: 2996908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-C1q column: ligand specific purification of immune complexes from human serum or plasma. Analysis of the interaction between C1q and immune complexes.
    Kilgallon W; Amlot PL; Williams BD
    Clin Exp Immunol; 1982 Jun; 48(3):705-14. PubMed ID: 6811171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of fibronectin on the processing of C1q- and C3b/bi-coated immune complexes by peripheral blood monocytes.
    Sorvillo JM; Gigli I; Pearlstein E
    J Immunol; 1986 Feb; 136(3):1023-6. PubMed ID: 3484498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating immune complexes in Plasmodium knowlesi infected Kra, and merozoite vaccinated Rhesus monkeys.
    Shepherd PS; Burke P; Thomas A; Mitchell GH; Cohen S
    Clin Exp Immunol; 1982 May; 48(2):315-20. PubMed ID: 6980742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between circulating immune complexes and renal disease in New Zealand mice.
    Nakai Y; Yoshida H; Maruyama N; Shirai T; Hamashima Y
    Clin Exp Immunol; 1981 Feb; 43(2):240-5. PubMed ID: 6974065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electron microscopy of the complement protein C1q from the bullfrog, Rana catesbeiana.
    Slayter HS; Alexander RJ; Steiner LA
    Eur J Immunol; 1983 Feb; 13(2):102-6. PubMed ID: 6601008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C1q binding and C1 activation by various isolated cellular membranes.
    Storrs SB; Kolb WP; Olson MS
    J Immunol; 1983 Jul; 131(1):416-22. PubMed ID: 6602834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of effector functions by immune complexes of mouse IgG2a with isotype-specific autoantibodies.
    Rajnavölgyi E; Fazekas G; Lund J; Daeron M; Teillaud JL; Jefferis R; Fridman WH; Gergely J
    Immunology; 1995 Apr; 84(4):645-52. PubMed ID: 7540592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.
    Bindon CI; Hale G; Waldmann H
    Eur J Immunol; 1988 Oct; 18(10):1507-14. PubMed ID: 2973413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between complement activation and renal deposition of immune complexes made with IgG2a monoclonal antibodies.
    Gonzalez ML; Waxman FJ
    Clin Immunol; 2001 Sep; 100(3):362-71. PubMed ID: 11513550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Origin of the classical complement pathway: Lamprey orthologue of mammalian C1q acts as a lectin.
    Matsushita M; Matsushita A; Endo Y; Nakata M; Kojima N; Mizuochi T; Fujita T
    Proc Natl Acad Sci U S A; 2004 Jul; 101(27):10127-31. PubMed ID: 15218103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q.
    Nauta AJ; Bottazzi B; Mantovani A; Salvatori G; Kishore U; Schwaeble WJ; Gingras AR; Tzima S; Vivanco F; Egido J; Tijsma O; Hack EC; Daha MR; Roos A
    Eur J Immunol; 2003 Feb; 33(2):465-73. PubMed ID: 12645945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of complement binding on a solid-phase immunometric TSH assay.
    Käpyaho K; Tanner P; Weber T
    Scand J Clin Lab Invest; 1989 May; 49(3):211-5. PubMed ID: 2662381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies against components of the classical pathway of complement.
    Heinz HP; Loos M
    Complement Inflamm; 1989; 6(3):166-74. PubMed ID: 2472920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating immune complexes in Behçet's syndrome: purification, characterization and cross-reactivity studies.
    Valesini G; Picardo M; Pastore R; Pivetti P; Serafini U
    Clin Exp Immunol; 1981 Jun; 44(3):522-7. PubMed ID: 6976862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.